Evolus, Inc. EOLS
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Evolus, Inc. (EOLS) is a healthcare company listed in the US with a market value of about $461M. In the twelve months to September 30, 2026 it had revenue of $325M and net income of -$31M, a net margin of -9.6%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 39% a year, a 5-year average ROIC of -31%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 64% below the current price.
About Evolus
Evolus is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $35M in 2019 to $297M in 2025, growth of about 42.9% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 15% over three years (dilution for shareholders). It spends 3% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year revenue growth above 8% a year
- ROE above 15%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $325M | $297M | $266M | $202M | $149M | $100M | $57M | $35M | $0 | — |
| Net income | -$31M | -$52M | -$50M | -$62M | -$74M | -$47M | -$163M | -$90M | -$47M | -$4M |
| Free cash flow | -$5M | -$46M | -$19M | -$34M | -$87M | -$34M | -$59M | -$94M | -$26M | -$13M |
| EPS (diluted) | $-0.47 | $-0.80 | $-0.81 | $-1.08 | $-1.33 | $-0.94 | $-4.83 | $-3.19 | $-1.92 | $-0.27 |
| Net margin | -9.6% | -17.4% | -18.9% | -30.5% | -50.1% | -47.0% | -288.3% | -257.8% | — | — |
| ROIC | — | -19.6% | -20.1% | -36.7% | -55.5% | -22.4% | — | -53.6% | -43.2% | -14.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $15.40, 121% above the current price; targets range from $12.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-0.03 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Evolus stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 64% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Evolus pay a dividend?
Not currently.
Is Evolus a good stock to buy?
We do not give buy or sell advice. Evolus scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.